Servicio de Angiología y Cirugía Vascular, Hospital del Mar, Barcelona, Spain.
Nefrologia. 2013;33(4):564-70. doi: 10.3265/Nefrologia.pre2012.Nov.11756.
INTRODUCTION/OBJECTIVE: The NKF-K/DOQI guidelines recommend that the repermeabilisation of thrombosed arteriovenous (AV) grafts for haemodialysis must achieve positive results in 40% at 3 months, if it is performed by endovascular technique, or 50% at 6 months and 40% at one year if it is performed by surgical procedure. This study assesses the results of a hybrid treatment (minimally invasive surgical and endovascular treatment) of AV graft thrombosis associated to venous anastomotic stenosis.
Between 2008 and 2012, 27 consecutive patients underwent surgery (average age: 69.7, 52% male) due to AV graft thrombosis associated to venous anastomotic stenosis (74.1% upper extremity) by open thrombectomy (mini-incision in the graft), covered self-expanding stent (Fluency, Bard), and high pressure angioplasty (>20atm).
Immediate patency with effective haemodialysis was 89%, with an average stay of 1.9 days and no postoperative complications. Primary patency at 3, 6, and 12 months was 51.9%, 44.4%, and 16.2% respectively (mean follow-up: 15 months). Secondary patency after a new thrombotic episode and similar procedure (62.9% of cases) was 70.4%, 51.9%, and 37% respectively.
Despite being safe and minimally invasive, this hybrid treatment for AV graft thrombosis associated to venous anastomotic stenosis only achieves competitive results compared to open surgery after a second iterative procedure. Because of this and the associated costs, this technique should be reserved for difficult surgical approach stenoses.
简介/目的:NKF-K/DOQI 指南建议,对于血栓形成的动静脉(AV)移植物,若采用血管内技术,则必须在 3 个月时达到 40%的再通率,若采用手术治疗,则必须在 6 个月时达到 50%,在 1 年时达到 40%,才能获得阳性结果。本研究评估了微创外科与血管内治疗联合治疗伴静脉吻合口狭窄的 AV 移植物血栓形成的效果。
2008 年至 2012 年,27 例连续患者因伴静脉吻合口狭窄的 AV 移植物血栓形成而行手术治疗(平均年龄:69.7 岁,52%为男性),采用开放血栓切除术(在移植物上做小切口)、带膜自膨式支架(Fluency,Bard)和高压血管成形术(>20atm)。
即时通畅率为 89%,可有效进行血液透析,平均住院时间为 1.9 天,无术后并发症。3、6 和 12 个月时的一期通畅率分别为 51.9%、44.4%和 16.2%(平均随访时间:15 个月)。再次发生血栓形成和类似手术(62.9%的病例)后的二次通畅率分别为 70.4%、51.9%和 37%。
尽管这种治疗伴静脉吻合口狭窄的 AV 移植物血栓形成的混合疗法安全且微创,但在进行第二次迭代手术后,与开放手术相比,仅能获得竞争性结果。由于这一点及其相关费用,该技术应保留用于治疗困难的手术入路狭窄。